Trial Profile

A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 With Recent Onset Stage 3 Type 1 Diabetes

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jun 2026 According to a COUR Pharma media release, the company announced it has closed a $50 million Series B funding round led by existing investors Lumira Ventures and Roche Venture Fund with participation from new investor, Sanofi. The proceeds will be used to support the clinical advancement of CNP-103.
19 Aug 2025 Status changed from not yet recruiting to recruiting.
19 Aug 2025 According to a Cour Pharmaceutical Development media release, first patient has been dosed in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com